AR088372A1 - Solucion para administracion oral - Google Patents

Solucion para administracion oral

Info

Publication number
AR088372A1
AR088372A1 ARP120103877A ARP120103877A AR088372A1 AR 088372 A1 AR088372 A1 AR 088372A1 AR P120103877 A ARP120103877 A AR P120103877A AR P120103877 A ARP120103877 A AR P120103877A AR 088372 A1 AR088372 A1 AR 088372A1
Authority
AR
Argentina
Prior art keywords
acid
oral administration
solution
compound
quinolin
Prior art date
Application number
ARP120103877A
Other languages
English (en)
Spanish (es)
Inventor
Kondo Ayako
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR088372A1 publication Critical patent/AR088372A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP120103877A 2011-10-19 2012-10-18 Solucion para administracion oral AR088372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19

Publications (1)

Publication Number Publication Date
AR088372A1 true AR088372A1 (es) 2014-05-28

Family

ID=47178263

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103877A AR088372A1 (es) 2011-10-19 2012-10-18 Solucion para administracion oral

Country Status (35)

Country Link
US (8) US20140303183A1 (OSRAM)
EP (1) EP2768508B1 (OSRAM)
JP (1) JP6077534B2 (OSRAM)
KR (1) KR101856283B1 (OSRAM)
CN (2) CN103889426A (OSRAM)
AR (1) AR088372A1 (OSRAM)
AU (2) AU2012326978B2 (OSRAM)
BR (1) BR112014009330A2 (OSRAM)
CA (1) CA2851999C (OSRAM)
CL (1) CL2014000967A1 (OSRAM)
CO (1) CO6950486A2 (OSRAM)
CY (1) CY1117794T1 (OSRAM)
DK (1) DK2768508T3 (OSRAM)
EA (2) EA201490812A1 (OSRAM)
ES (1) ES2583137T3 (OSRAM)
HR (1) HRP20160989T1 (OSRAM)
HU (1) HUE028869T2 (OSRAM)
IL (1) IL231988A (OSRAM)
IN (1) IN2014DN02987A (OSRAM)
JO (1) JO3190B1 (OSRAM)
LT (1) LT2768508T (OSRAM)
ME (1) ME02459B (OSRAM)
MX (1) MX347309B (OSRAM)
MY (1) MY169096A (OSRAM)
PH (1) PH12014500816A1 (OSRAM)
PL (1) PL2768508T3 (OSRAM)
PT (1) PT2768508T (OSRAM)
RS (1) RS54967B1 (OSRAM)
SG (1) SG11201401273SA (OSRAM)
SI (1) SI2768508T1 (OSRAM)
SM (1) SMT201600341B (OSRAM)
TW (2) TWI632921B (OSRAM)
UA (1) UA111506C2 (OSRAM)
WO (1) WO2013058411A1 (OSRAM)
ZA (1) ZA201402669B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
UA124498C2 (uk) * 2015-12-01 2021-09-29 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти)
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
WO2019075127A1 (en) * 2017-10-10 2019-04-18 Vertice Pharma, Llc ORAL MICODRIN HYDROCHLORIDE SOLUTION AND USES THEREOF
JPWO2021029020A1 (OSRAM) * 2019-08-13 2021-02-18
JP2021115288A (ja) * 2020-01-28 2021-08-10 青葉化成株式会社 液状組成物および液状医療材料
WO2022006205A1 (en) 2020-06-30 2022-01-06 Vireo Systems, Inc. Compositions and methods for treatment of vaginal infections
US20210401879A1 (en) * 2020-06-30 2021-12-30 Vireo Systems, Inc. Compositions for controlling odor and itch and methods of and devices for administering same
CN115192548A (zh) * 2021-04-13 2022-10-18 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用
CN115414322A (zh) * 2022-07-05 2022-12-02 杭州民生药物研究院有限公司 一种富马酸卢帕他定口服液体制剂及其制备工艺
CN116966140A (zh) * 2023-08-18 2023-10-31 四川阿赛斯生物科技有限公司 一种含有布瑞哌唑的口服溶液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EP1507765A4 (en) * 2002-05-03 2006-11-02 Israel Inst Biolog Res METHODS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND RELATED COMPOUNDS
EP1741438A4 (en) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1891956B1 (en) * 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
JP5189980B2 (ja) * 2005-09-01 2013-04-24 バクスター・インターナショナル・インコーポレイテッド 可溶化剤として酸を含むアルガトロバン処方物
JP2009545515A (ja) * 2006-07-31 2009-12-24 アスビオファーマ株式会社 液状製剤
WO2009038701A2 (en) * 2007-09-17 2009-03-26 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
WO2009039324A1 (en) 2007-09-21 2009-03-26 Forest Laboratories Holdings Limited Soluble dosage forms containing cephem derivatives suitable for parenteral administration
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
AR082494A1 (es) * 2010-08-24 2012-12-12 Otsuka Pharma Co Ltd Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途

Also Published As

Publication number Publication date
PH12014500816A1 (en) 2014-05-19
SMT201600341B (it) 2016-11-10
CL2014000967A1 (es) 2014-10-03
ME02459B (me) 2017-02-20
CA2851999A1 (en) 2013-04-25
CY1117794T1 (el) 2017-05-17
CA2851999C (en) 2020-01-07
UA111506C2 (uk) 2016-05-10
PL2768508T3 (pl) 2016-12-30
PT2768508T (pt) 2016-08-17
AU2012326978A1 (en) 2014-05-22
MX347309B (es) 2017-04-21
IL231988A (en) 2017-09-28
US20140303183A1 (en) 2014-10-09
NZ623523A (en) 2015-12-24
HRP20160989T1 (hr) 2016-10-07
TWI679977B (zh) 2019-12-21
CN103889426A (zh) 2014-06-25
IL231988A0 (en) 2014-05-28
KR20140083032A (ko) 2014-07-03
IN2014DN02987A (OSRAM) 2015-05-08
BR112014009330A2 (pt) 2017-04-11
HK1196773A1 (zh) 2014-12-24
RS54967B1 (sr) 2016-11-30
DK2768508T3 (en) 2016-08-29
HUE028869T2 (en) 2017-01-30
SG11201401273SA (en) 2014-05-29
EA201490812A1 (ru) 2014-09-30
CN107823131A (zh) 2018-03-23
TW201330873A (zh) 2013-08-01
US20180271858A1 (en) 2018-09-27
JO3190B1 (ar) 2018-03-08
SI2768508T1 (sl) 2016-09-30
TW201737916A (zh) 2017-11-01
EP2768508B1 (en) 2016-07-06
US20160213665A1 (en) 2016-07-28
US20210236483A1 (en) 2021-08-05
US20170182036A1 (en) 2017-06-29
US20250099460A1 (en) 2025-03-27
ES2583137T3 (es) 2016-09-19
EP2768508A1 (en) 2014-08-27
CO6950486A2 (es) 2014-05-20
AU2012326978B2 (en) 2017-08-31
ZA201402669B (en) 2015-09-30
MX2014004529A (es) 2014-08-01
JP2014530801A (ja) 2014-11-20
TWI632921B (zh) 2018-08-21
JP6077534B2 (ja) 2017-02-08
AU2017213570A1 (en) 2017-08-31
WO2013058411A1 (en) 2013-04-25
US20200171023A1 (en) 2020-06-04
LT2768508T (lt) 2016-09-12
EA202190445A2 (ru) 2021-08-31
KR101856283B1 (ko) 2018-05-09
MY169096A (en) 2019-02-18
US20240009186A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
AR088372A1 (es) Solucion para administracion oral
PH12012502568A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
EA201390347A1 (ru) Лечение заболеваний
EA201792597A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
EA200900397A1 (ru) Новые соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501425A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta-cyclodextrin
AR083100A1 (es) Monohidrato de derivados de aza-adamantano
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
TH148781A (th) สารละลายสำหรับการให้ทางช่องปาก
TH97363B (th) สารละลายสำหรับการให้ทางช่องปาก
UA106336U (uk) Сполука n-феніл-3-(уридин-2'-тіо-4'-гідроксі-6'-аміно)-сукцинімід, яка має потенційну фізіологічну властивість
TH152447A (th) องค์ประกอบทางเภสัชกรรม
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
TH159388A (th) สารประกอบแมคโครไซคลิคและวิธีการผลิตของมัน
TH128481A (th) 11-(2-ไพร์โรลิดิน-1-อิล-เอทอกซี)-14,19-ไดออกซา-5,7,26-ไตรอะซา-เตตราไซโคล [19.3.1.1(2,6).1(8,12)]เฮปทาโคซา-1(25),2(26),3,5,8,10,12(27),16,21,23-เดคาอีน ซิเตรท ซอลท์
TH154733A (th) อนุพันธ์เตตระไฮโดร-ไพริโด-ไพริมิดีน (tetrahydro-pyrido-pyrimidine)
HK1184972A1 (zh) 化合物及用於抑制磷酸盐转运的方法
RU2009128860A (ru) Способ лечения заболеваний пародонта у мужчин при частичном возрастном андрогенном дефиците

Legal Events

Date Code Title Description
FC Refusal